$AXP

JPMorgan reveals stocks worth buying in October 2026

JPMorgan added five stocks to its Overweight list, highlighting American Express (AXP) as a Value pick, Thermo Fisher (TMO) and Liberty Energy (LBRT) as Growth picks. AXP is down 18-19% YTD but JPMorgan sees steady profits and share buybacks. TMO is up 25% in 3 months, with growth driven by partnerships and AI-powered lab machines. LBRT is up 52% in 12 months, benefiting from AI data center power demands.

Original reporting
Published Oct 6, 2026, 7:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JPMorgan reveals stocks worth buying in October 2026 — source image
Decision brief

The 30-second read

$AXPBullishMed
01

Why it matters

The new recommendations provide fresh analyst endorsement, likely prompting short‑term buying pressure on the named stocks.

02

Market read

Analyst overweight designations can move small‑cap stocks and influence sector sentiment, especially in AI‑related themes.

03

What to watch

Potential credit risk for AXP and commodity price exposure for LBRT could temper enthusiasm.

Relevance 7/10Novelty 7/10Timing: today

Background

JPMorgan released its latest Overweight list, adding three stocks as top picks for value and growth strategies.

Company-level read

Ticker impact

$AXPBullishHigh confidence
Context

JPMorgan added American Express as its main Value pick in the new Overweight list, indicating a fresh analyst endorsement.

Expected impact

likely upward pressure as the stock gains attention from the new overweight rating

Evidence & confidence

Analyst overweight adds credibility and may trigger buying from JPMorgan‑following funds.

$TMOBullishHigh confidence
Context

Thermo Fisher was highlighted as a Growth pick, with JPMorgan noting a partnership with Mayo Clinic and AI‑lab machine potential.

Expected impact

likely upward pressure as investors price in the growth narrative

Evidence & confidence

The analyst’s bullish comments and partnership highlight new revenue avenues.

$LBRTBullishHigh confidence
Context

Liberty Energy was named a Growth pick tied to AI data‑center power demand, with JPMorgan citing a multi‑year demand runway.

Expected impact

likely upward pressure as the stock benefits from the analyst’s AI‑power thesis

Evidence & confidence

Analyst focus on a niche growth theme can attract capital to a small‑cap name.

Market effects

Highlights a shift toward AI‑related energy and biotech growth themes, potentially lifting related sector ETFs.

U.S. equities may see modest gains in financial and industrial sectors as analysts adjust weightings.

Limited to U.S. markets; no immediate global macro impact.

Counterpoint

Some investors may view the picks as overvalued given recent price runs and could be cautious.

Key entities

  • JPMorgan Chase

    Issuer of the Overweight list and analyst recommendations.

  • American Express

    Credit‑card issuer highlighted as a Value pick.

  • Thermo Fisher Scientific

    Biotech equipment supplier highlighted as a Growth pick.

  • Liberty Energy

    Energy firm highlighted for AI‑data‑center power demand.

Related articles

$QNTMMed

Quantum BioPharma Taps Thermo Fisher for Lucid-MS Phase 2 Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has partnered with Thermo Fisher Scientific to begin Phase 2 trials for Lucid-MS, a treatment for progressive multiple sclerosis. The FDA has cleared the trial, which will assess efficacy, safety, and tolerability. Thermo Fisher will provide clinical research services. Success could offer a new treatment option for MS, a condition with limited therapies. Quantum owns 19.84% of Unbuzzd Wellness and receives royalties from it.

$QNTMMedAI 8/10

Quantum BioPharma Advances Multiple Sclerosis Trial with Thermo Fisher Partnership

Quantum BioPharma (QNTM) partnered with Thermo Fisher Scientific to start a Phase 2 trial for Lucid-MS, a treatment for progressive multiple sclerosis. The trial, cleared by the FDA, will assess efficacy, safety, and tolerability. Lucid-MS targets myelin degradation, differing from existing therapies. Quantum owns 19.84% of Unbuzzd Wellness, with royalty agreements in place.

$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.